Connection

Diane Descamps to Humans

This is a "connection" page, showing publications Diane Descamps has written about Humans.
Connection Strength

0.134
  1. Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients. Eur J Clin Microbiol Infect Dis. 2021 Oct; 40(10):2235-2241.
    View in: PubMed
    Score: 0.007
  2. Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen. J Antimicrob Chemother. 2018 04 01; 73(4):1039-1044.
    View in: PubMed
    Score: 0.006
  3. Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations. Viruses. 2018 01 18; 10(1).
    View in: PubMed
    Score: 0.006
  4. Severe Reinfection With South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant 501Y.V2. Clin Infect Dis. 2021 11 16; 73(10):1945-1946.
    View in: PubMed
    Score: 0.002
  5. The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. J Infect. 2021 10; 83(4):e1-e3.
    View in: PubMed
    Score: 0.002
  6. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses. 2021 08 19; 13(8).
    View in: PubMed
    Score: 0.002
  7. High-sensitivity SARS-CoV-2 group testing by digital PCR among symptomatic patients in hospital settings. J Clin Virol. 2021 08; 141:104895.
    View in: PubMed
    Score: 0.002
  8. Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March-May 2020). Clin Microbiol Infect. 2021 Oct; 27(10):1520.e1-1520.e5.
    View in: PubMed
    Score: 0.002
  9. Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection. J Infect Dis. 2021 05 20; 223(9):1522-1527.
    View in: PubMed
    Score: 0.002
  10. Contribution of rapid lateral flow assays from capillary blood specimens to the diagnosis of COVID-19 in symptomatic healthcare workers: a pilot study in a university hospital, Paris, France. Diagn Microbiol Infect Dis. 2021 Oct; 101(2):115430.
    View in: PubMed
    Score: 0.002
  11. The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. J Infect. 2021 Jul; 83(1):119-145.
    View in: PubMed
    Score: 0.002
  12. Performance evaluation of the QIAstat-Dx® Respiratory SARS-CoV-2 Panel. Int J Infect Dis. 2021 Jun; 107:179-181.
    View in: PubMed
    Score: 0.002
  13. Viral epidemiology and SARS-CoV-2 co-infections with other respiratory viruses during the first COVID-19 wave in Paris, France. Influenza Other Respir Viruses. 2021 07; 15(4):425-428.
    View in: PubMed
    Score: 0.002
  14. High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort. J Infect. 2021 05; 82(5):186-230.
    View in: PubMed
    Score: 0.002
  15. Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity. Nat Immunol. 2021 03; 22(3):322-335.
    View in: PubMed
    Score: 0.002
  16. Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study. PLoS One. 2020; 15(12):e0243961.
    View in: PubMed
    Score: 0.002
  17. Characteristics associated with COVID-19 or other respiratory viruses' infections at a single-center emergency department. PLoS One. 2020; 15(12):e0243261.
    View in: PubMed
    Score: 0.002
  18. Arterial Thrombotic Events in Adult Inpatients With COVID-19. Mayo Clin Proc. 2021 02; 96(2):295-303.
    View in: PubMed
    Score: 0.002
  19. Reply to Yan and Muller, "Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity". Antimicrob Agents Chemother. 2020 11 17; 64(12).
    View in: PubMed
    Score: 0.002
  20. Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19. Antimicrob Agents Chemother. 2020 10 20; 64(11).
    View in: PubMed
    Score: 0.002
  21. Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and one IgG automated immunoassay (Abbott). J Clin Virol. 2020 11; 132:104618.
    View in: PubMed
    Score: 0.002
  22. Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report. J Antimicrob Chemother. 2020 09 01; 75(9):2706-2707.
    View in: PubMed
    Score: 0.002
  23. Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients. J Antimicrob Chemother. 2020 09 01; 75(9):2657-2660.
    View in: PubMed
    Score: 0.002
  24. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med. 2020 09 02; 12(559).
    View in: PubMed
    Score: 0.002
  25. Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2. J Clin Virol. 2020 Sep; 130:104573.
    View in: PubMed
    Score: 0.002
  26. SARS-CoV-2 IGM and IGG rapid serologic test for the diagnosis of COVID-19 in the emergency department. J Infect. 2020 11; 81(5):816-846.
    View in: PubMed
    Score: 0.002
  27. Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection. J Clin Microbiol. 2020 Jul 23; 58(8).
    View in: PubMed
    Score: 0.002
  28. New insights in COVID-19-associated chilblains: A comparative study with chilblain lupus erythematosus. J Am Acad Dermatol. 2020 Oct; 83(4):1219-1222.
    View in: PubMed
    Score: 0.002
  29. Evaluation of the RealStar® SARS-CoV-2 RT-PCR kit RUO performances and limit of detection. J Clin Virol. 2020 08; 129:104520.
    View in: PubMed
    Score: 0.002
  30. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis. 2020 Jul; 26(7):1478-1488.
    View in: PubMed
    Score: 0.002
  31. Challenges and issues about organizing a hospital to respond to the COVID-19 outbreak: experience from a French reference centre. Clin Microbiol Infect. 2020 Jun; 26(6):669-672.
    View in: PubMed
    Score: 0.002
  32. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020 06; 20(6):697-706.
    View in: PubMed
    Score: 0.002
  33. Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence? J Antimicrob Chemother. 2020 01 01; 75(1):183-193.
    View in: PubMed
    Score: 0.002
  34. New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017. Euro Surveill. 2019 Sep; 24(39).
    View in: PubMed
    Score: 0.002
  35. Prevalence of Human Papillomavirus, Human Immunodeficiency Virus, and Other Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo: A National Cross-sectional Survey. Clin Infect Dis. 2019 08 30; 69(6):1019-1026.
    View in: PubMed
    Score: 0.002
  36. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. J Antimicrob Chemother. 2019 07 01; 74(7):2019-2023.
    View in: PubMed
    Score: 0.002
  37. Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients. J Antimicrob Chemother. 2019 07 01; 74(7):1992-2002.
    View in: PubMed
    Score: 0.002
  38. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. J Antimicrob Chemother. 2019 06 01; 74(6):1679-1692.
    View in: PubMed
    Score: 0.002
  39. Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France. J Antimicrob Chemother. 2019 05 01; 74(5):1417-1424.
    View in: PubMed
    Score: 0.002
  40. Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients. J Antimicrob Chemother. 2019 05 01; 74(5):1368-1375.
    View in: PubMed
    Score: 0.002
  41. Piloting a surveillance system for HIV drug resistance in the European Union. Euro Surveill. 2019 May; 24(19).
    View in: PubMed
    Score: 0.002
  42. New insights are game-changers in HIV-2 disease management. Lancet HIV. 2019 04; 6(4):e214.
    View in: PubMed
    Score: 0.002
  43. New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). Chem Biol Drug Des. 2019 01; 93(1):50-59.
    View in: PubMed
    Score: 0.002
  44. Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir. J Antimicrob Chemother. 2018 10 01; 73(10):2716-2720.
    View in: PubMed
    Score: 0.002
  45. First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2). Clin Infect Dis. 2018 09 28; 67(8):1161-1167.
    View in: PubMed
    Score: 0.002
  46. Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing. J Antimicrob Chemother. 2018 09 01; 73(9):2485-2492.
    View in: PubMed
    Score: 0.002
  47. Presence of Human Papillomavirus (HPV) Apolipoprotein B Messenger RNA Editing, Catalytic Polypeptide-Like 3 (APOBEC)-Related Minority Variants in HPV-16 Genomes From Anal and Cervical Samples but Not in HPV-52 and HPV-58. J Infect Dis. 2018 08 24; 218(7):1027-1036.
    View in: PubMed
    Score: 0.002
  48. Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study). J Antimicrob Chemother. 2018 08 01; 73(8):2147-2151.
    View in: PubMed
    Score: 0.002
  49. High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort. J Antimicrob Chemother. 2018 06 01; 73(6):1665-1671.
    View in: PubMed
    Score: 0.002
  50. Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants. PLoS One. 2018; 13(6):e0198334.
    View in: PubMed
    Score: 0.002
  51. Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases. J Clin Microbiol. 2018 06; 56(6).
    View in: PubMed
    Score: 0.002
  52. Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals. Clin Infect Dis. 2018 05 17; 66(11):1785-1793.
    View in: PubMed
    Score: 0.002
  53. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. Clin Infect Dis. 2018 05 02; 66(10):1588-1594.
    View in: PubMed
    Score: 0.002
  54. Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients. J Antimicrob Chemother. 2018 05 01; 73(5):1173-1176.
    View in: PubMed
    Score: 0.002
  55. Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis. J Antimicrob Chemother. 2018 04 01; 73(4):1108-1110.
    View in: PubMed
    Score: 0.002
  56. Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads. J Virol Methods. 2018 07; 257:12-15.
    View in: PubMed
    Score: 0.002
  57. Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. Eur J Clin Pharmacol. 2018 Apr; 74(4):473-481.
    View in: PubMed
    Score: 0.002
  58. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. J Antimicrob Chemother. 2018 Jan 01; 73(1):173-176.
    View in: PubMed
    Score: 0.001
  59. Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients. J Antimicrob Chemother. 2017 10 01; 72(10):2954-2955.
    View in: PubMed
    Score: 0.001
  60. Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load. J Clin Virol. 2017 11; 96:49-53.
    View in: PubMed
    Score: 0.001
  61. HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors. J Antimicrob Chemother. 2017 09 01; 72(9):2431-2437.
    View in: PubMed
    Score: 0.001
  62. Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma. J Antimicrob Chemother. 2017 08 01; 72(8):2351-2354.
    View in: PubMed
    Score: 0.001
  63. Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016. PLoS One. 2017; 12(7):e0180888.
    View in: PubMed
    Score: 0.001
  64. New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification. J Clin Microbiol. 2017 09; 55(9):2850-2857.
    View in: PubMed
    Score: 0.001
  65. Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort. J Antimicrob Chemother. 2017 06 01; 72(6):1745-1751.
    View in: PubMed
    Score: 0.001
  66. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study. J Antimicrob Chemother. 2017 06 01; 72(6):1769-1773.
    View in: PubMed
    Score: 0.001
  67. Disparities in HIV-1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations. HIV Med. 2017 10; 18(9):696-700.
    View in: PubMed
    Score: 0.001
  68. Impact of respiratory viruses in hospital-acquired pneumonia in the intensive care unit: A single-center retrospective study. J Clin Virol. 2017 06; 91:52-57.
    View in: PubMed
    Score: 0.001
  69. Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study. J Antimicrob Chemother. 2017 04 01; 72(4):1137-1146.
    View in: PubMed
    Score: 0.001
  70. Usefulness of multiplex PCR methods and respiratory viruses' distribution in children below 15 years old according to age, seasons and clinical units in France: A 3 years retrospective study. PLoS One. 2017; 12(2):e0172809.
    View in: PubMed
    Score: 0.001
  71. Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Antimicrob Agents Chemother. 2013 May; 57(5):2265-71.
    View in: PubMed
    Score: 0.001
  72. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009 Nov 01; 49(9):1441-9.
    View in: PubMed
    Score: 0.001
  73. Parenteral transmission of Kaposi's sarcoma-associated herpesvirus. AIDS. 1998 Dec 03; 12(17):2351.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.